All three major U.S. stock indexes ended in the red, and all remain on track for weekly declines.
All three major U.S. stock indexes ended in the red, and all remain on track for weekly declines. All three major U.S. stock indexes ended in the red, and all remain on track for weekly declines. Moneycontrol Latest News Read More
All three major U.S. stock indexes ended in the red, and all remain on track for weekly declines.
Brent crude futures climbed 45 cents, or 0.5%, to $88.38 a barrel by 0019 GMT while U.S. West Texas Intermediate was at $83.63 a barrel, up 42 cents, or 0.5%.
Brent crude futures climbed 45 cents, or 0.5%, to $88.38 a barrel by 0019 GMT while U.S. West Texas Intermediate was at $83.63 a barrel, up 42 cents, or 0.5%. Brent crude futures climbed 45 cents, or 0.5%, to $88.38 a barrel by 0019 GMT while U.S. West Texas Intermediate was at $83.63 a barrel, up 42 cents, or 0.5%. Moneycontrol Latest News Read More
Brent crude futures climbed 45 cents, or 0.5%, to $88.38 a barrel by 0019 GMT while U.S. West Texas Intermediate was at $83.63 a barrel, up 42 cents, or 0.5%.
Tesla Inc has increased the price for its Model Y high-performance version SUV in China by 14,000 yuan ($1,913.88) from Friday, it said on a social media notice.
Tesla Inc has increased the price for its Model Y high-performance version SUV in China by 14,000 yuan ($1,913.88) from Friday, it said on a social media notice. Tesla Inc has increased the price for its Model Y high-performance version SUV in China by 14,000 yuan ($1,913.88) from Friday, it said on a social media notice. Moneycontrol Latest News Read More
Tesla Inc has increased the price for its Model Y high-performance version SUV in China by 14,000 yuan ($1,913.88) from Friday, it said on a social media notice.
The consolidated total income for the reporting quarter stood at Rs 20.84 crore, decreasing by 1.70 percent YoY, compared to Rs 21.20 crore recorded in the same quarter a year ago
The consolidated total income for the reporting quarter stood at Rs 20.84 crore, decreasing by 1.70 percent YoY, compared to Rs 21.20 crore recorded in the same quarter a year ago The consolidated total income for the reporting quarter stood at Rs 20.84 crore, decreasing by 1.70 percent YoY, compared to Rs 21.20 crore recorded in the same quarter a year ago Moneycontrol Latest News Read More
The consolidated total income for the reporting quarter stood at Rs 20.84 crore, decreasing by 1.70 percent YoY, compared to Rs 21.20 crore recorded in the same quarter a year ago
Earlier this month Bollywood actors Akshay Kumar and Kangna Ranaut have also visited the film city site in YEIDA sector 21 which is located adjacent to the Yamuna Expressway.
Earlier this month Bollywood actors Akshay Kumar and Kangna Ranaut have also visited the film city site in YEIDA sector 21 which is located adjacent to the Yamuna Expressway. Earlier this month Bollywood actors Akshay Kumar and Kangna Ranaut have also visited the film city site in YEIDA sector 21 which is located adjacent to the Yamuna Expressway. Moneycontrol Latest News Read More
Earlier this month Bollywood actors Akshay Kumar and Kangna Ranaut have also visited the film city site in YEIDA sector 21 which is located adjacent to the Yamuna Expressway.
Based on the OI percentage, 155 stocks, including Dr Lal PathLabs, Delta Corp, RBL Bank, Navin Fluorine International and ONGC, saw a long unwinding
Based on the OI percentage, 155 stocks, including Dr Lal PathLabs, Delta Corp, RBL Bank, Navin Fluorine International and ONGC, saw a long unwinding Based on the OI percentage, 155 stocks, including Dr Lal PathLabs, Delta Corp, RBL Bank, Navin Fluorine International and ONGC, saw a long unwinding Moneycontrol Latest News Read More
Based on the OI percentage, 155 stocks, including Dr Lal PathLabs, Delta Corp, RBL Bank, Navin Fluorine International and ONGC, saw a long unwinding
To ensure that small investors don#39;t get pulled in by high-risk strategies, SEBI has proposed that this new category- if the proposal goes through- should have a higher minimal investment barrier.
To ensure that small investors don#39;t get pulled in by high-risk strategies, SEBI has proposed that this new category- if the proposal goes through- should have a higher minimal investment barrier. To ensure that small investors don#39;t get pulled in by high-risk strategies, SEBI has proposed that this new category- if the proposal goes through- should have a higher minimal investment barrier. Moneycontrol Latest News Read More
To ensure that small investors don#39;t get pulled in by high-risk strategies, SEBI has proposed that this new category- if the proposal goes through- should have a higher minimal investment barrier.
Geojit recommended reduce rating on Hindustan Zinc with a target price of Rs 258 in its research report dated October 25, 2023.
Geojit recommended reduce rating on Hindustan Zinc with a target price of Rs 258 in its research report dated October 25, 2023. Geojit recommended reduce rating on Hindustan Zinc with a target price of Rs 258 in its research report dated October 25, 2023. Moneycontrol Latest News Read More
Geojit recommended reduce rating on Hindustan Zinc with a target price of Rs 258 in its research report dated October 25, 2023.
Its revenue from operations stood at Rs 10,716.3 crore, rising 0.95 percent from 10,614.6 crore in the corresponding quarter, the company said in an exchange filing.
Its revenue from operations stood at Rs 10,716.3 crore, rising 0.95 percent from 10,614.6 crore in the corresponding quarter, the company said in an exchange filing. Its revenue from operations stood at Rs 10,716.3 crore, rising 0.95 percent from 10,614.6 crore in the corresponding quarter, the company said in an exchange filing. Moneycontrol Latest News Read More
Its revenue from operations stood at Rs 10,716.3 crore, rising 0.95 percent from 10,614.6 crore in the corresponding quarter, the company said in an exchange filing.
Simulect is an intravenous prescription drug that is used on transplant patients to ensure the body does not reject the new organ.
Simulect is an intravenous prescription drug that is used on transplant patients to ensure the body does not reject the new organ. Simulect is an intravenous prescription drug that is used on transplant patients to ensure the body does not reject the new organ. Moneycontrol Latest News Read More
Simulect is an intravenous prescription drug that is used on transplant patients to ensure the body does not reject the new organ.
हिन्दी 
English